Armata Pharmaceuticals (ARMP) Assets Average (2014 - 2026)

Armata Pharmaceuticals (ARMP) has 13 years of Assets Average data on file, last reported at $73.3 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average fell 15.55% year-over-year to $73.3 million; the trailing twelve-month figure through Mar 2026 stood at $73.3 million (down 15.55% YoY), and the FY2025 full-year result was $81.7 million, down 11.62% from the prior year.
• Assets Average retreated to $73.3 million in Q1 2026, from $83.2 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $114.3 million in Q2 2024 to a low of $73.3 million in Q1 2026.
• A 5-year average of $96.2 million and a median of $96.9 million in 2022 frame the typical range for Assets Average.
• Across the five-year window, Assets Average soared 113.15% in 2022 and dropped 26.51% in 2025, its largest moves.
• Tracing ARMP's Assets Average over 5 years: stood at $94.4 million in 2022, then rose by 11.87% to $105.6 million in 2023, then decreased by 12.53% to $92.3 million in 2024, then declined by 9.9% to $83.2 million in 2025, then retreated by 11.85% to $73.3 million in 2026.
• Business Quant data shows ARMP's Assets Average at $73.3 million in Q1 2026, $83.2 million in Q4 2025, and $85.2 million in Q3 2025.